Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations

被引：0
|
作者：
Yukiko Shimoda
Tatsuya Yoshida
Jun Miyakoshi
Masahiro Torasawa
Akiko Tateishi
Yuji Matsumoto
Ken Masuda
Yuki Shinno
Yusuke Okuma
Yasushi Goto
Hidehito Horinouchi
Noboru Yamamoto
Yuichiro Ohe
机构：
[1] National Cancer Center Hospital,Department of Thoracic Oncology
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
来源：
Cancer Immunology, Immunotherapy | 2023年 / 72卷
关键词：
Non-small cell lung cancer; Sequential therapy; Dosing interval; Serious adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2613 / 2621
页数：8
相关论文
共 50 条
  • [1] Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations
    Shimoda, Yukiko
    Yoshida, Tatsuya
    Miyakoshi, Jun
    Torasawa, Masahiro
    Tateishi, Akiko
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2613 - 2621
  • [2] Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
    Shimoda, Yukiko
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S483
  • [3] A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor
    Sawada, Takashi
    Narukawa, Mamoru
    CANCER CONTROL, 2024, 31
  • [4] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2023, 18 (01) : 159 - 168
  • [5] Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma
    Hiroki Ishihara
    Yuki Nemoto
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2023, 18 : 159 - 168
  • [6] Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
    Sayer, Michael R.
    Mambetsariev, Isa
    Lu, Kun-Han
    Wong, Chi Wah
    Duche, Ashley
    Beuttler, Richard
    Fricke, Jeremy
    Pharoan, Rebecca
    Arvanitis, Leonidas
    Eftekhari, Zahra
    Amini, Arya
    Koczywas, Marianna
    Massarelli, Erminia
    Roosan, Moom Rahman
    Salgia, Ravi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Response to treatment of cutaneous immune-related adverse events following immune checkpoint inhibitor therapy
    Reardon, R. M.
    Perlman, K. L.
    Asdourian, M.
    Shah, N.
    Jacoby, T.
    Thompson, L. L.
    Reynolds, K.
    Chen, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S87 - S87
  • [8] Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
    Muir, Christopher A.
    Clifton-Bligh, Roderick J.
    Long, Georgina, V
    Scolyer, Richard A.
    Lo, Serigne N.
    Carlino, Matteo S.
    Tsang, Venessa H. M.
    Menzies, Alexander M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (09): : E3704 - E3713
  • [9] Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
    Le, Thomas K.
    Kaul, Subuhi
    Cappelli, Laura C.
    Naidoo, Jarushka
    Semenov, Yevgeniy R.
    Kwatra, Shawn G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1691 - 1695
  • [10] CUTANEOUS ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITOR THERAPY: INCIDENCE AND TYPES OF REACTIVE DERMATOSES
    Le, Thomas
    Kaul, Subuhi
    Wongvibulsin, Shannon
    Cappelli, Laura
    Naidoo, Jarushka
    Semenov, Yevgeniy
    Kwatra, Shawn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A509 - A510
12345